Zobrazeno 1 - 10
of 3 733
pro vyhledávání: ''
Autor:
Julia Nazco-Casariego, Laura Ramos, Fernando Gutiérrez-Nicolás, Raquel De La Barreda, Enrique Quintero, Inmaculada Alonso-Abreu, Javier Ramos-Rodríguez, Marta Carrillo-Palau
Publikováno v:
Gastroenterología y Hepatología (English Edition). 45:335-341
Nonadherence to medication is common in patients with inflammatory bowel disease (IBD) and can result in disease complications, therapy escalation, and the need for corticosteroids. The aim of this study was to assess the adherence to self-administer
Autor:
Markus Cornberg, Christoph Höner zu Siederdissen, George N. Dalekos, Fabien Zoulim, Milan J. Sonneveld, Wai-Kay Seto, Nicole S. Erler, Heiner Wedemeyer, Thomas Berg, Ivana Carey, Jun Yong Park, Kosh Agarwal, Yasuhito Tanaka, Sang Hoon Ahn, Benjamin Maasoumy, Apichat Kaewdech, Teerha Piratvisuth, Maria Buti, Man-Fung Yuen, George V. Papatheodoridis, Andre Boonstra, Margarita Papatheodoridi, Florian van Bömmel
Publikováno v:
Clinical Gastroenterology and Hepatology, 20(4), e784-e793. W.B. Saunders
Background & Aims: Predictors of successful nucleo(s)tide analogue (NA) therapy withdrawal remain elusive. We studied the relationship between end-of-treatment levels of hepatitis B core-related antigen (HBcrAg) and hepatitis B surface antigen (HBsAg
Autor:
Anil Arora, Nishant Verma, Prateek Shivshankar Padole, Praveen Sharma, Prakash Chand, Ashok Kumar
Publikováno v:
J Clin Exp Hepatol
BACKGROUND: Saroglitazar is a novel, dual peroxisome proliferator-activated receptors-α/γ agonist and is being investigated for the treatment of nonalcoholic fatty liver disease (NAFLD). PATIENTS AND METHODS: Consecutive overweight (body mass index
Autor:
Dana J. Lukin, Paul J. Christos, Robert Battat, Waseem Ahmed, Jonathan S. Galati, Ellen Scherl, Anand Kumar, Randy S. Longman
Publikováno v:
Clinical Gastroenterology and Hepatology. 20:e361-e379
Background and Aims We conducted a systematic review and meta-analysis to summarize emerging data on the safety and effectiveness of dual biologic therapy in combination or with tofacitinib in patients with refractory inflammatory bowel disease (IBD)
Autor:
Nilay Shah, Lindsey R. Sangaralingham, Parambir S. Dulai, Herbert C. Heien, William J. Sandborn, Jeph Herrin, Siddharth Singh
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol 20, iss 2
Clin Gastroenterol Hepatol
Clin Gastroenterol Hepatol
Background and Aims We conducted a retrospective cohort study comparing the risk of serious infections between patients treated with tumor necrosis factor-a (TNFa) antagonists vs. vedolizumab in patients with inflammatory bowel diseases (IBD). Method
Autor:
Yiran Zhang, Satimai Aniwan, A Weiss, Gursimran Kochhar, Sunanda V. Kane, Bo Shen, Matthew Bohm, Siddharth Singh, Eugenia Shmidt, Jean-Frederic Colombel, Corey A. Siegel, David Faleck, Edward V. Loftus, James P. Campbell, Mahmoud A. Rahal, Siri Kadire, Ronghui Xu, William J. Sandborn, David Hudesman, Arun Swaminath, Joseph Meserve, Robert Hirten, Vipul Jairath, Ryan C. Ungaro, Bruce E. Sands, Karen Lasch, Jenna L. Koliani-Pace, Brigid S. Boland, Parambir S. Dulai, Dana J. Lukin, Shreya Chablaney, Monika Fischer, Adam Winters, Gloria Tran, Shannon Chang, Sashidhar Varma
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol 20, iss 1
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol 20, iss 1
Background & Aims We aimed to compare safety and effectiveness of vedolizumab to tumor necrosis factor (TNF)-antagonist therapy in ulcerative colitis in routine practice. Methods A multicenter, retrospective, observational cohort study (May 2014 to D
Autor:
Rafael Sartori Balbinot, Silvana Sartori Balbinot, Louise Zanotto Eberhardt, Raul Angelo Balbinot, Gilberto Luis Rost, Juline Isabel Leichtweis Balensiefer, Ana Laura Facco Muscope, Bruna Schena, Morgana Luisa Longen, Alana Zulian Terres, Jonathan Soldera, Bruna Teston Cini
Publikováno v:
Gastroenterología y Hepatología. 45:25-39
Hepatorenal syndrome (HRS) is the deadliest complication of cirrhosis. The purpose of this study is to analyze if the use of a protocol for HRS is associated with higher survival in these patients.An evidence-based protocol for the diagnosis and trea
Publikováno v:
Gastroenterología y Hepatología. 44:671-679
Resumen Objetivo Estudiar las caracteristicas epidemiologicas, clinicas y la respuesta al tratamiento en pacientes con colitis microscopica. Pacientes y metodo Se recopilaron retrospectivamente los datos epidemiologicos, clinicos, analiticos y endosc
Autor:
Annarosa Floreani, Sara De Martin
Publikováno v:
Digestive and Liver Disease. 53:1531-1538
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by progressive fibro-stenotic strictures and destruction of the biliary tree. Currently, there is no effective treatment which can delay its progression or amel
Autor:
Sarah Maylin, Julie Chas, Caroline Lascoux-Combe, Audrey Gabassi, Lorenza N C Dezanet, Karine Lacombe, Constance Delaugerre, Hayette Rougier, Patrick Miailhes, Anders Boyd
Publikováno v:
Liver international, 41(12), 2874-2884. Wiley-Blackwell
BACKGROUND & AIMS: Data on liver fibrosis evolution and its involvement in liver-related morbidity are scarce in individuals with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) co-infection during treatment. We identified profiles of